Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
David A. Rider, Mona Eisermann, Kathrin Löffler, Manuela Aleku, Daniel I. Swerdlow, Sibylle Dames, Judith Hauptmann, Eliot Morrison, Marie Lindholm, Steffen Schubert, G. Campion
Topics & Concepts
In vivoGene knockdownPharmacologyApolipoprotein BDosingMedicinePharmacokineticsIn vitroBiomarkerPCSK9PharmacodynamicsLipoprotein(a)LipoproteinInternal medicineEndocrinologyChemistryLDL receptorBiologyCholesterolBiochemistryApoptosisBiotechnologyLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism